

NO: 31 or SEQ ID NO: 32 and wherein the peptide has cortistatin or somatostatin activity.

C1
cancel
2. (amended) A peptide as claimed in Claim 1 which comprises the amino acid sequence defined under SEQ ID NO: 1 or an amino acid sequence derived therefrom by deletion or substitution of 1 to 5 amino acid residues.

cancel
D17
C2
6. (twice amended) An isolated peptide having the amino acid sequence defined under any of SEQ ID NO: 35 through SEQ ID NO: 55 or a salt of said peptide, wherein the peptide has cortistatin or somatostatin activity.

7. (amended) A peptide as claimed in Claim 1 which comprises the amino acid sequence defined under SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, or SEQ ID NO: 7.

Please cancel claim 8, without prejudice.

C3
18. (amended) A pharmaceutical composition which comprises the peptide or salt claimed in Claim 1.

Please cancel claim 20, without prejudice.

cancel
D27
C4
24. (amended) A kit for screening for a compound, or a salt thereof, which is capable of modifying the binding of the peptide or salt claimed in Claim 1 to a receptor for said peptide or salt, or a fragment peptide, which kit comprises the peptide or salt claimed in Claim 1.

Please add the following new claims:

cancel
D3
C5
--35. An isolated peptide comprising the amino acid sequence defined under any one of SEQ ID NO:1 to SEQ ID NO:3 and SEQ ID NO:35 to SEQ ID NO:55 and having cortistatin or somatostatin activity.

36. An isolated peptide comprising the amino acid sequence defined under any one of SEQ ID NO:1 to SEQ ID NO:3, SEQ ID NO:35 to SEQ ID NO:42 and SEQ ID NO:44 to SEQ ID NO:55 and having cortistatin or somatostatin activity.

37. An isolated peptide comprising (i) the amino acid sequence defined under any one of SEQ ID NO:4 to SEQ ID NO:7, and SEQ ID NO:56 to SEQ ID NO:61 or (ii) the amino acid sequence derived from the amino acid sequence defined under any one of and SEQ ID NO:4 to SEQ ID NO:7 by deletion of the C-terminal Lys.--

REMARKS

In the above referenced application, Claims 1-8, 18, 20 and 24 are pending in the above referenced application and stand rejected. Claims 1, 2, 6, 7, 8, 18 and 24 have been amended to more particularly set forth and distinctly claim the present invention. In particular, claims 1 and 6 have been amended to recite that the peptide has cortistatin or somatostatin activity. Claim 7 has been amended to recite a "peptide", instead of a "precursor". Claims 1, 2, 6, 18 and 20 have been amended to delete "precursor". New claims 35-37 have been added to include claims to peptides having particular SEQ ID Nos. Support for the amendments is found throughout the specification. For example, claim 35 is supported by items (1) to (23) of pages 22 to 27 and claim 8, claim 36 is supported by items (1) to (10) and (12) to (23) of pages 22 to 27 and claim 8, claim 37 is supported by items (1) to (7) and claim 7. Thus, no new matter has been added by these amendments. In light of the above amendments and following discussion, Applicant respectfully requests that the outstanding rejections be withdrawn and the claims be allowed.

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is entitled "VERSIONS WITH MARKINGS TO SHOW CHANGES MADE."